Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $9.5 million.

  • Cytokinetics' Depreciation & Amortization (CF) rose 11.12% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 28.45%. This contributed to the annual value of $9.5 million for FY2024, which is 19.85% down from last year.
  • Cytokinetics' Depreciation & Amortization (CF) amounted to $9.5 million in FY2024, which was down 19.85% from $11.9 million recorded in FY2023.
  • Cytokinetics' Depreciation & Amortization (CF)'s 5-year high stood at $11.9 million during FY2023, with a 5-year trough of $1.8 million in FY2020.
  • In the last 3 years, Cytokinetics' Depreciation & Amortization (CF) had a median value of $9.5 million in 2024 and averaged $9.1 million.
  • As far as peak fluctuations go, Cytokinetics' Depreciation & Amortization (CF) skyrocketed by 155.45% in 2022, and later decreased by 19.85% in 2024.
  • Yearly analysis of 5 years shows Cytokinetics' Depreciation & Amortization (CF) stood at $1.8 million in 2020, then grew by 24.30% to $2.3 million in 2021, then soared by 155.45% to $5.8 million in 2022, then soared by 104.54% to $11.9 million in 2023, then dropped by 19.85% to $9.5 million in 2024.